BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Biocad readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Biocad's drugs run\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07742215-3129@assetmemo.bio
DTSTAMP:20261121T005833Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Torutamig: Phase 3 readout est. (NCT07742215)
DESCRIPTION:Torutamig\, phase 3\, Multiple Myeloma.\nStudy: A Study of the 
 Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients
  With Relapsed or Refractory Multiple Myeloma (AMMADINA)\nEstimated primar
 y completion: July 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/torutamig#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07742215
URL:https://assetmemo.bio/drug/torutamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07321093-7129@assetmemo.bio
DTSTAMP:20261121T005833Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:BCD-281: Phase 3 readout est. (NCT07321093)
DESCRIPTION:BCD-281\, phase 3\, Multiple Sclerosis.\nStudy: A Study of the 
 Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multip
 le Sclerosis\nEstimated primary completion: December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bcd-281#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07321093
URL:https://assetmemo.bio/drug/bcd-281#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
